Skip to search formSkip to main contentSkip to account menu

NSC 368390

Known as: NSC-368390 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

brequinar

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Inhibition of pyrimidine de novo synthesis by DUP-785 (NSC 368390)
The mechanism of action of NSC 368390 (DUP-785, 6-fluoro-2-(2′-fluoro-1, 1′-biphenyl-4-yl)-3-methyl-4-quinoline carboxylic acid… 
2004
2004
Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies
SummaryBrequinar sodium (DUP 785, NSC 368390) is a novel quinoline-carboxylic acid derivative that has been selected for clinical… 
1998
1998
Pharmacokinetic and phase I studies of brequinar (DUP 785; NSC 368390) in combination with cisplatin in patients with advanced malignancies
Brequinar (DUP 785; NSC 368390) is a quinoline carboxylic acid derivative that inhibits pyrimidine synthesis at the level of… 
1992
1992
In vitro and in vivo studies on the combination of Brequinar sodium (DUP-785; NSC 368390) with 5-fluorouracil; effects of uridine.
Brequinar sodium (DUP-785; Brequinar) is a potent inhibitor of the pyrimidine de novo enzyme dihydroorotate dehydrogenase (DHO-DH… 
Highly Cited
1990
Highly Cited
1990
In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.
Little is known about the in vivo effects of inhibition of the mitochondrial pyrimidine de novo synthesis enzyme dihydroorotic… 
1990
1990
Phase I and pharmacokinetic study of brequinar sodium (NSC 368390).
Brequinar sodium is a quinoline carboxylic acid derivative that has shown antitumor activity in a number of in vivo murine and… 
Highly Cited
1989
Highly Cited
1989
Phase I clinical and pharmacokinetic trial of Brequinar sodium (DuP 785; NSC 368390).
Brequinar sodium is a 4-quinolinecarboxylic acid analogue that inhibits dihydroorotate dehydrogenase and subsequent de novo… 
1989
1989
Pharmacokinetics of Brequinar sodium (NSC 368390) in patients with solid tumors during a phase I study.
1988
1988
DUP 785 (NSC 368390): schedule-dependency of growth-inhibitory and antipyrimidine effects.
Highly Cited
1985
Highly Cited
1985
Activity of a novel 4-quinolinecarboxylic acid, NSC 368390 [6-fluoro-2-(2'-fluoro-1,1'-biphenyl-4-yl)-3-methyl-4-quinolinecarb oxylic acid sodium salt], against experimental tumors.
A novel, substituted 4-quinolinecarboxylic acid (NSC 339768) demonstrated antitumor activity against L1210 leukemia and B16… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)